PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

HDR brachytherapy of prostate cancer
Article published in Urologia Polska 2007/60/2.

authors

Marek Kanikowski 1, Janusz Skowronek 1, Piotr Milecki 2, Magda Kubaszewska 1, Adam Chicheł 1
1 Zakład Brachyterapii, Wielkopolskie Centrum Onkologii w Poznaniu
2 Zakład Radioterapii, Wielkopolskie Centrum Onkologii w Poznaniu

keywords

prostate, prostate cancer, HDR brachytherapy, external beam radiation therapy, radioisotopes, temporary implants

summary

Brachytherapy is one of the oldest methods in treatment of tumors known from the beginning of XX century. Generally the main idea of this method is to implant radioactive source and to provide radiation dose directly into the tumor mass. HDR brachytherapy (HDR - BT) in treatment of prostate cancer is most frequently used together with external beam radiation therapy (EBRT) as a boost (increasing treatment dose exactly to the tumor). In some cases HDR - BT is used as a sole radical treatment modality or as a palliative treatment. There are no significant differences in treatment results between radical prostatectomy, EBRT and HDR brachytherapy. The use of radiation therapy as a treatment of prostate cancer enables many patients to keep their sexual functions in order and causes lower rate of incontinence. According to progress in medical and technical knowledge in brachytherapy (development of computer planning systems, new radioisotopes and remote - afterloading systems), there has been possible to make treatment time significantly shorter in comparison with external beam radiation therapy and enables a higher protection of healthy organs in the pelvis. The aim of this publication is to describe method, indications, complications and selected results of prostate cancer HDR - BT.

references

  1. Urologists and Radiation Oncologists Agree on Some Aspects of Prostate Cancer Treatment but Not on Which Is Best. AHRQ Public Affairs 2000, (301), 427-1364.
  2. Makarewicz R: Brachyterapia HDR. Gdańsk, Wydawnictwo Via Medica, 2004, rozdz. 14, 95-99.
  3. Wronczewska A, Makarewicz R, Wronczewski A: Brachyterapia raka gruczołu krokowego. Współ Onkol 2000, 1, 33-36.
  4. Kovacs G, Potter R, Loch T et al: GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 2005, 74, 137-148.
  5. Fijałkowski M, Białas B, Maciejewski B i in: Three-dimensional (3D) real-time conformal brachytherapy - a novel solution for prostate cancer treatment. Part I. Rationale and method. Nowotwory 2005, 1, 58-65.
  6. Fijałkowski M, Białas B, Maciejewski B i in: Three-dimensional (3D) real-time conformal brachytherapy - a novel solution for prostate cancer treatment. Part II. A feasibility clinical pilot study. Nowotwory 2005, 2, 115-121.
  7. Holm HH, Juul N, Pedersen JF et al: Transperineal J-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983, 130, 283-286.
  8. Wolski Z: Brachyterapia raka gruczołu krokowego. Przegl Urol 2002, 6, 26-33.
  9. Leibel SA, Phillips TL: Textbook of Radiation Oncology, Second Edition 2004, Chapter 45, 988-1000.
  10. Garbaulet A, Potter R, Mazeron JJ et al: The GEC ESTRO Handbook of Brachytherapy, Brussels, 2002, Chapter 20, 473-480.
  11. Nag S, Baird J, Blasko JC et al: American Brachytherapy Society Survey of Current Clinical Practice for Permanent Brachytherapy of Prostate Cancer. J Brachytherapy Int 1997, 13, 243-251.
  12. Wallner K, Blasko JC, Cavanagh W: Brachytherapy in the management of prostate cancer. In Radiotherapeutic management of prostate adenocarcinoma. Oxford University Press 1999, 135-150, New York.
  13. Villers A, Pommier P, Bataillard A et al: Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001). Brit J Cancer 2003, 89, 50-58.
  14. Bertermann H, Brix F: Ultrasonically guided interstitial high-dose rate brachytherapy with 192Ir: technique and preliminary results in locally confined prostate cancer. W: Martinez AA, Orton, CG, Mould RF, red. Brachytherapy HDR and LDR: remote afterloading state-of-the-art. Columbia: Nucletron 1990, 281-303.
  15. Mate TP: High Dose Rate prostate brachytherapy with 192 Iridium: the Seattle experience. Nowotwory 2003, 1, 34-37.
  16. Martinez AA, Gustafson G, Gonzalez J et al: Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53, 316-327.
  17. Syed N, Puthawala A, Barth N et al: High Dose Rate Brachytherapy in the treatment of carcinoma of the prostate: Preliminary results. J Brachytherapy Int 1997, 6, 315-331.
  18. Morton GC: The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005, 17, 219-227.
  19. Kovacs G, Galalae R: Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary? Cancer Radiother 2003, 7, 100-106.
  20. Pellizzon AC, Nadalin W, Salvajoli JV et al: Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 2003, 66, 167-172.
  21. Andreopoulos D, Piatkowiak M, Krenkel B et al: Combined treatment of localized prostate cancer with HDR - Iridium 192 remote brachytherapy and external beam irradiation. Strahlenter Oncol 1999, 175, 387-391.
  22. Demanes DJ, Rodriguez RR, Altieri GA: High dose rate prostate brachytherapy: the California Endocurietherapy (CET). Method Radiother Oncol 2000, 57, 289-296.
  23. Ślosarek K, Bystrzycka J, Fijałkowski M: Real time brachytherapy for prostate cancer - A new challenge for medical physicists. Rep Pract Oncol Radiother 2005, 10, 255-259.
  24. Blasko J, Ragde H, Grimm P: Transperineal ultrasound guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991, 137, 113-118.
  25. Tran A, Wallner K, Merrick G et al: Rectal fistulas after prostate brachytherapy. Int J Rad Oncol Biol Phys 2005, 63, 150-154.
  26. Mate TP, Gottesman JE, Hatton J et al: High dose-rate afterloading 192 Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998, 41, 525-533.
  27. Astrom L, Pedersen D, Mercke C et al: Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005, 74, 157-161.
  28. Prada Gomez PJ, de la Rua Calderon A, Romo Fonesca I et al: High dose brachytherapy (real time) in patients with intermediate - or high risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol 2005, 7, 389-397.
  29. Hsu IC, Cabrera AR, Weinberg V et al: Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy 2005, 4, 202-206.
  30. Hiratsuka J, Jo Y, Yoshida K et al: Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59, 684-690.
  31. Agoston P, Major T, Somogyi A et al: Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary. Magy Onkol 2004, 48, 81-88.
  32. Martin T, Roddiger S, Kurek R et al: 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 2000; 71, 35-41.
  33. Yoshioka Y, Nose T, Yoshida K et al: High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000, 48, 675-681.
  34. Wolski Z, Wronczewski A, Makarewicz R, Wronczewska A: Brachyterapia wysokodawkowa wraz z napromienianiem z pól zewnętrznych w leczeniu chorych z rakiem stercza. Urol Pol 2006, 1, 40-44.

correspondence

Marek Kanikowski
Wielkopolskie Centrum Onkologii Zakład Brachyterapii
ul. Garbary 15
61-866 Poznań
tel. (061) 885 08 32, 0 601860436
marekk0@poczta.onet.pl